Total revenues slipped 2% in Q2 2026 to $783.3 million, while net income rose 8% to $333.0 million. The company highlighted record Tyvaso DPI growth and two NDAs submitted for ralinepag and Nebulized Tyvaso in IPF.
Total revenues slipped 2% in Q2 2026 to $783.3 million, while net income rose 8% to $333.0 million. The company highlighted record Tyvaso DPI growth and two NDAs submitted for ralinepag and Nebulized Tyvaso in IPF.